Glucagon and glp-1 co-agonists for the treatment of obesity

Abstract

Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonist peptides.

1 - 69 . (canceled) 
     
     
         70 . A method of reducing body fat comprising administering to a human subject in need thereof 50-600 μg of a peptide comprising the amino acid sequence of SEQ ID NO: 19. 
     
     
         71 . A method of treating obesity comprising administering to a human subject in need thereof 50-600 μg of a peptide comprising the amino acid sequence of SEQ ID NO: 19. 
     
     
         72 . (canceled) 
     
     
         73 . A method of managing weight comprising administering to a human subject in need thereof 50-600 μg of a peptide comprising the amino acid sequence of SEQ ID NO: 19. 
     
     
         74 - 121 . (canceled) 
     
     
         122 . The method of any one of  claims 70 ,  71 , and  73 , wherein the administration results in weight loss of at least 1.0 kg, at least 1.3 kg, or about 1.3 to about 2.0 kg. 
     
     
         123 . The method of any one of  claims 70 ,  71 , and  73 , wherein the subject's weight is reduced by at least 3.5 kg or at least 5 kg. 
     
     
         124 . The method of any one of  claims 70 ,  71 , and  73 , wherein the subject's weight is reduced by about 2 to about 30 kg. 
     
     
         125 . The method of any one of  claims 70 ,  71 , and  73 , wherein the subject's weight is reduced by at least 2%, at least 4%, at least 5%, or at least 10%. 
     
     
         126 . The method of any one of  claims 70 ,  71 , and  73 , wherein the subject's weight is reduced by about 2% to about 20%, about 2% to about 25%, or about 2% to about 30%. 
     
     
         127 - 177 . (canceled)